Zymergen raises 300 M$ to accelerate the manufacturing of its biobased Hyaline film
Type of post: NEWS IN BRIEF.
Zymergen, a synthetic biology start-up, has raised 300 M$ in financing. The new capital will be used to accelerate manufacturing of the company’s Hyaline film, which could be seen in commercial applications next year.
Zymergen blog: “Series D Investments to Accelerate the Products of Tomorrow”, 8/9/2020.
Figure 1. Hyaline films deliver unique combinations of high transparency, high temperature resistance, and excellent mechanical properties (taken from the company website). The co-development partner for the Hyaline product is Sumitomo Chemical in Japan.
The Series D investment included funds from Baillie Gifford, Baron Capital and others, as well as returning investors. This new influx will boost the release of products across the consumer electronics and agriculture sectors. In fact, Hyaline product will be shipping to key electronics customers in the coming months.
Hyaline is a biobased specialty film in the polyimide family that delivers unique combinations of high transparency, high temperature resistance and excellent mechanical properties. Perfect for touch screens, optical filters for camera lenses and wearable sensors, it enables thinner screens and faster manufacturing times.